AbbVie Inc.: reports expected 3rd quarter 2026 acquired IPR&D expense of $216,000,000

What happened AbbVie Inc reported that GAAP earnings and adjusted non-GAAP earnings for the 3rd quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216,000,000 on a pre-tax basis, representing an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. The filing says results for the quarter ended Sep 30, 2026 have not been finalized and are subject to the company’s financial statement closing procedures, and there can be no assurance that final results will not differ from these preliminary estimates.

Key details

• Acquired IPR&D and milestones expense: $216,000,000 (pre-tax)
• EPS impact: unfavorable $0.11 to GAAP diluted EPS and to adjusted non-GAAP diluted EPS
• Full-year 2026 adjusted diluted EPS guidance range, including the 3rd quarter impact: $13.76 - $13.96
• 3rd quarter 2026 adjusted diluted EPS guidance range, including the 3rd quarter impact: $3.73 - $3.77

Why it may matter This item was reported under Item 2.02 (results of operations and financial condition) and covers the expected inclusion of acquired IPR&D and milestones expense in AbbVie’s 3rd quarter 2026 results and the related adjusted EPS guidance ranges. A filing does not show why the insider traded or why the company acted.